The Health Care M&A Monthly: Private Equity In The Middle Market-
Private Equity Firms Continue To Find Good Deals Email Editor Financial entities, such as REITS and private equity firms, continue to make their mark in the health care M&A market. During April, financial concerns were involved in 11 transactions, either as...The Health Care M&A Monthly: AstraZeneca Grabs MedImmune-$15.2 Billion Deal Is Largest Biotech Transaction Ever
Email Editor April’s M&A market produced the largest biotechnology deal ever seen. Britain’s AstraZeneca plc (NYSE: AZN) announced that it is buying MedImmune (NASDAQ: MEDI) for $58.00 per share, or $15.2 billion. In AZN’s sights are MEDI’s vaccine business and...The SeniorCare Investor: Battle For Genesis Escalates –
Two Bidders Up Their Offers, But Outcome Up In The Air During the weeks before the shareholder vote to approve the sale of Genesis HealthCare (NASDAQ: GHCI) to a joint venture between Formation Capital and JER Partners, it became apparent that the necessary votes were...The SeniorCare Investor: Manor Care Suprises Market–
But Is A Sale Of The Company Really In The Cards? It has been apparent that the skilled nursing industry has been in the crosshairs of the capital-abundant equity firms, hedge funds and any others with enough money to pull off a multi-billion-dollar transaction. The...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
